Synergen Inc. has licensed R&D Systems, a wholly ownedsubsidiary of Techne Corp. (NASDAQ:TECH), to develop andmarket Synergen's biomolecules as reagents and in diagnostickits for the basic research and clinical diagnostic markets.

Synergen's proteins included in the collaboration areinterleukin-1 receptor antagonist, basic fibroblast growthfactor, secretory leukocyte protease inhibitor and tumornecrosis factor binding proteins.

"The main reason we're doing this is that we want to focus ontherapeutics and not diagnostics," said Kenneth Collins, vicepresident of finance at Boulder, Colo.-based Synergen(NASDAQ:SYGN).

R&D systems, based in Minneapolis, will pay Synergen a royaltyon sales. R&D Systems will have exclusive U.S. rights and non-exclusive rights in other countries. No further details weredisclosed.

(c) 1997 American Health Consultants. All rights reserved.